Hoth Therapeutics (HOTH) News Today $0.79 +0.01 (+1.78%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.78 -0.01 (-0.71%) As of 04/17/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Hoth Therapeutics’ HT-001 shows efficacy in Phase 2a pruritus trialApril 17 at 11:01 PM | markets.businessinsider.comHoth Therapeutics granted Japanese patent for novel RNA-based cancer therapyApril 17 at 11:01 PM | markets.businessinsider.comHoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology PlatformApril 17 at 8:01 AM | prnewswire.comHoth Therapeutics reports interim data from Phase IIa trial of HT-001 for pruritusApril 17 at 2:57 AM | msn.comHoth Therapeutics, Inc.: Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical TrialApril 15 at 8:15 PM | finanznachrichten.deHoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical TrialApril 15 at 8:19 AM | prnewswire.comHoth Therapeutics announces collaboration with Washington UniversityApril 3, 2025 | markets.businessinsider.comHoth Therapeutics reports data from its Alzheimer’s candidate HT-ALZApril 2, 2025 | markets.businessinsider.comHoth Flat on Hookup with Washington Univ.April 2, 2025 | baystreet.caHoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZApril 2, 2025 | prnewswire.comHoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hoursApril 2, 2025 | prnewswire.comHoth Therapeutics receives USPTO filing receipt for HT-001 patent applicationApril 1, 2025 | markets.businessinsider.comHoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent CoverageMarch 31, 2025 | prnewswire.comHoth Therapeutics, Inc.: Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study InitiationMarch 26, 2025 | finanznachrichten.deHoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study InitiationMarch 26, 2025 | prnewswire.comHoth Therapeutics to Revise Financial Statements Due to Auditing ErrorsMarch 25, 2025 | marketwatch.comHoth Therapeutics announces ‘positive’ results from study of HT-KITMarch 20, 2025 | finance.yahoo.comHoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatmentMarch 18, 2025 | prnewswire.comHoth Therapeutics, Inc.: Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in NeedMarch 10, 2025 | finanznachrichten.deHoth Dips on Drug ApplicationMarch 10, 2025 | baystreet.caHoth Therapeutics to submit Expanded Access application for HT-001March 10, 2025 | markets.businessinsider.comHoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in NeedMarch 10, 2025 | prnewswire.comHoth Therapeutics’ GDNF shows efficacy in obesity prevention and reversalMarch 5, 2025 | markets.businessinsider.comHoth Therapeutics reports ‘promising’ results for HT-001 therapeutic candidateMarch 5, 2025 | markets.businessinsider.comHoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual MeetingMarch 5, 2025 | prnewswire.comHoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver DiseaseMarch 4, 2025 | prnewswire.comHoth Therapeutics announces collaboration with OnTargetx R&DFebruary 10, 2025 | markets.businessinsider.comHoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer TherapeuticFebruary 10, 2025 | prnewswire.comHoth Therapeutics expands at-the-market offering by $5 millionFebruary 8, 2025 | msn.comHoth Therapeutics regains compliance with Nasdaq listing rulesJanuary 25, 2025 | markets.businessinsider.comHoth Therapeutics Restores Compliance With Nasdaq Listing RequirementsJanuary 24, 2025 | markets.businessinsider.comHoth Therapeutics Regains Compliance with Nasdaq Listing RequirementsJanuary 24, 2025 | prnewswire.comHoth Therapeutics expands cancer drug patent portfolioJanuary 21, 2025 | msn.comHoth Therapeutics Expands IP Portfolio With New Patent ApplicationsJanuary 21, 2025 | markets.businessinsider.comHoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent ApplicationsJanuary 21, 2025 | prnewswire.comHoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025January 17, 2025 | prnewswire.comHoth Therapeutics: Strong balance sheet includes over $10M cash, no debtJanuary 10, 2025 | markets.businessinsider.comHoth Therapeutics affirms no plans for public, private offering at this timeJanuary 10, 2025 | markets.businessinsider.comHoth Therapeutics responds to market rumors, says no plans for offeringJanuary 10, 2025 | markets.businessinsider.comHoth Therapeutics Shares Recover; Company Has No Plans for OfferingJanuary 9, 2025 | marketwatch.comHoth Therapeutics Responds to Market Rumors and Shareholder InquiriesJanuary 8, 2025 | prnewswire.comShares Of This Micro Cap More Than Doubled TodayJanuary 8, 2025 | msn.comHoth Therapeutics reports ‘encouraging’ results from Phase 2a trial of HT-001January 8, 2025 | markets.businessinsider.comD. Boral says Hoth findings highlight HT-001 potential to ‘revolutionize’ careJanuary 8, 2025 | markets.businessinsider.comHoth Therapeutics’ Stock Triples On Promising Cancer Trial Data for Skin Toxicity Therapy: Retail’s ExcitedJanuary 8, 2025 | msn.comHoth Therapeutics Shares Hit 52-Week High on Positive Data for Cancer TreatmentJanuary 7, 2025 | marketwatch.comHoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin ToxicitiesJanuary 7, 2025 | prnewswire.comHoth Therapeutics partners with Dept. of Veterans Affairs on obesity treatmentDecember 27, 2024 | markets.businessinsider.comWhy Hoth Therapeutics Is Rising In Pre-market?December 26, 2024 | markets.businessinsider.comHoth licenses patents to develop anti-obesity treatmentsDecember 26, 2024 | msn.com Get Hoth Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter. Email Address HOTH Media Mentions By Week HOTH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HOTH News Sentiment▼0.220.49▲Average Medical News Sentiment HOTH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HOTH Articles This Week▼71▲HOTH Articles Average Week Get Hoth Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Century Therapeutics News Applied Therapeutics News Tenaya Therapeutics News Shattuck Labs News Skye Bioscience News Mersana Therapeutics News Actinium Pharmaceuticals News OnKure Therapeutics News Aadi Bioscience News Celularity News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HOTH) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThey Won’t Tell You This About GoldInflation, digital currency, and government policy are quietly eating away at your savings — and most people w...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hoth Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hoth Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
